Acasti Pharma Inc. reports quarterly results

Laval, Québec, CANADA – January 29th, 2009 – Acasti Pharma Inc.today announced its financial results for the three-month period and six-month period ended November 30, 2008.

Acasti Pharma’s President, Dr. Tina Sampalis pointed out that Acasti Pharma started operations in August 2008 with the objective to advance the pharmaceutical applications of its product portfolio in cardiovascular disease.

In the fiscal quarter ended November 30, 2008, Acasti Pharma created a loss of $234,000 and for the six-month period ended November 30, 2008, a loss of $371,000. Acasti Pharma is researching and developing novel active pharmaceutical ingredients for cardiovascular applications and the expenses can be mainly attributed to R&D; expenses and administrative expenses, initially supported by the parent company Neptune Technologies & Bioressources Inc.

Acasti Pharma’s fiscal year will end on February 28, 2009.

About Acasti Pharma Inc.
Acasti Pharma’s product portfolio of proprietary novel long-chain omega-3 phospholipids are sourced from sustainable abundant marine biomass including Antarctic krill (Euphausia superba). Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and play, as such, an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions.

Acasti Pharma is a subsidiary of Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT; TSX.V:NTB).

NASDAQ does not accept responsibility for the adequacy or accuracy of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Acasti Pharma Contact:
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it